• Report Adverse Event or Product Quality Complaint
  • US Site
  • Global Site
AstraZeneca Medical Information
  • Therapy Areas
    • All Therapeutic Areas
    • Cardiovascular
    • Immunology
    • Infection
    • Metabolic
    • Oncology
    • Renal
    • Respiratory
    • Rare Disease (Alexion)
  • Medications
  • Resources
    • Congress Library
    • Disease Education
    • Pipeline
    • Clinical Trials
    • Open innovation
    • Access 360
    • Affordability Programs
    • Sample Closet
    • Medical Education Grant
    • Rare Disease (Alexion)
  • Connect
    • Connect with Us
    • Find an MSL
    • Request an MSL
    • Submit an MIR
    • Give Feedback
User
  • Login to My AZmedical
  • Register for My AZmedical

Search Medical Information

European Society of Hypertension (ESH) – 34th European Meeting on Hypertension and Cardiovascular Protection - 2025

May 23 - 26, 2025

  1. Hypertension

pdf

Baseline characteristics of patients in BaxHTN: a phase 3 trial of the aldosterone synthase inhibitor baxdrostat in patients with uncontrolled or resistant hypertension

pdf

Graphical abstract of Baseline characteristics of patients in BaxHTN: a phase 3 trial of the aldosterone synthase inhibitor baxdrostat in patients with uncontrolled or resistant hypertension

pdf

Epidemiology and clinical burden of disease among uncontrolled and treatment-resistant hypertension patients: A systematic literature review

pdf

Graphical abstract of Epidemiology and clinical burden of disease among uncontrolled and treatment-resistant hypertension patients: A systematic literature review

pdf

Spironolactone in the treatment of uncontrolled and treatment-resistant hypertension: A systematic literature review

pdf

Graphical abstract of Spironolactone in the treatment of uncontrolled and treatment-resistant hypertension: A systematic literature review

html

High rates of mineralocorticoid receptor antagonist discontinuation in patients with hypertension: Insights from the EnligHTN study

pdf

Inadequately controlled hypertension – patient profiles in Germany and Spain: Insights from the EnligHTN study

pdf

Graphical abstract of Inadequately controlled hypertension – patient profiles in Germany and Spain: Insights from the EnligHTN study

html

Medication profiles in patients with inadequately controlled hypertension: Insights from the EnligHTN study

Disclaimer

Some content may have changed since publication. Some links may require registration/login to access the content. Any attached publications and/or any tables or figures derived from the publications are copyright-protected works. AstraZeneca has obtained permission from the copyright owner to use this work on this site. You may not reproduce, prepare derivative works from, display or distribute this work unless you obtain the permission of the copyright owner, or as otherwise might be permitted by law.

Request a field medical follow-up

Welcome to AstraZeneca
Medical Information

The information provided on this site is intended for use by healthcare professionals practicing in the US. The dissemination of this information may be subject to different medical and regulatory requirements in other countries.

This web site is intended to help healthcare professionals practicing in the US and AstraZeneca authorized persons find scientifically balanced, evidence-based information about AstraZeneca drugs, submit a question, ask for field medical follow-up, and explore links to professional and patient support resources.

Are you a healthcare professional practicing in the United States?

I am an AstraZeneca authorized person   What is an AstraZeneca authorized person?This website is only intended for healthcare professionals practicing in the United States and authorized AstraZeneca personnel. AstraZeneca US Headquarters personnel and US Field Medical personnel are authorized to browse and search the database for their own background knowledge and insight. US Field Sales personnel should not access or browse this site. None of the content of this site should be directly linked or distributed without approval.
I am a payer or formulary decision-maker
I am neither (take me to AstraZeneca.com)
AstraZeneca Logo
Pharma Logo

This site is intended for healthcare professionals practicing in the US.

©2022 AstraZeneca. All rights reserved.

US-69609

Last Updated 11/22

Contact Us

About Us

AstraZeneca-US.com

Grant Opportunities

Survey Feedback

Your Privacy Choices

Privacy Notice

Legal Notice

Cookie Notice

US Site

Global Site

Report Adverse Event or Product Quality Complaint

Pharma Logo

Privacy NoticeLegal NoticeCookie Notice